119 related articles for article (PubMed ID: 3141672)
21. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
22. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.
Podbesek R; Edouard C; Meunier PJ; Parsons JA; Reeve J; Stevenson RW; Zanelli JM
Endocrinology; 1983 Mar; 112(3):1000-6. PubMed ID: 6822201
[TBL] [Abstract][Full Text] [Related]
23. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
Sone T; Fukunaga M; Ono S; Nishiyama T
Miner Electrolyte Metab; 1995; 21(1-3):232-5. PubMed ID: 7565456
[TBL] [Abstract][Full Text] [Related]
24. Effects of disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP) in adult normal and selectively parathyroidectomized rats. I. Effects on plasma calcium, bone tissue, and adrenal glands at low or normal calcium intake.
Larsson SE; Ahlgren O
Metab Bone Dis Relat Res; 1982; 4(2):121-7. PubMed ID: 6815414
[TBL] [Abstract][Full Text] [Related]
25. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.
Liu CC; Kalu DN; Salerno E; Echon R; Hollis BW; Ray M
J Bone Miner Res; 1991 Oct; 6(10):1071-80. PubMed ID: 1796755
[TBL] [Abstract][Full Text] [Related]
26. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate.
Worth H; Stammen D; Keck E
Am J Respir Crit Care Med; 1994 Aug; 150(2):394-7. PubMed ID: 8049820
[TBL] [Abstract][Full Text] [Related]
27. Preliminary observations of a form of coherence therapy for osteoporosis.
Anderson C; Cape RD; Crilly RG; Hodsman AB; Wolfe BM
Calcif Tissue Int; 1984 May; 36(3):341-3. PubMed ID: 6432299
[TBL] [Abstract][Full Text] [Related]
28. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone in the treatment of osteoporosis.
Fujita T
BioDrugs; 2001; 15(11):721-8. PubMed ID: 11707147
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Buxton EC; Yao W; Lane NE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
[TBL] [Abstract][Full Text] [Related]
31. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis and management of primary osteoporosis.
Bauwens SF; Drinka PJ; Boh LE
Clin Pharm; 1986 Aug; 5(8):639-59. PubMed ID: 3527528
[TBL] [Abstract][Full Text] [Related]
33. [Sodium etidronate (EHDP) and osteoporosis].
Nuti R; Righi G; Turchetti V; Vattimo A
Clin Ter; 1981 Oct; 99(1):33-42. PubMed ID: 6171376
[No Abstract] [Full Text] [Related]
34. Pharmacological effects of a recombinant hPTH(1-34) derived peptide on ovariectomized rats.
Chunxiao W; Chengying G; Liang J; Xiaoming S; Feng G; Junting Y; Wenhui W; Yu W; Jingjing L
Eur J Pharmacol; 2017 Jan; 794():193-200. PubMed ID: 27887949
[TBL] [Abstract][Full Text] [Related]
35. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
36. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
[TBL] [Abstract][Full Text] [Related]
37. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo.
Hock JM; Hummert JR; Boyce R; Fonseca J; Raisz LG
J Bone Miner Res; 1989 Jun; 4(3):449-58. PubMed ID: 2527459
[TBL] [Abstract][Full Text] [Related]
38. [Inhibition of prednisolone osteopathy by diphosphonate (EHDP) in an animal experiment].
Trzenschik K; Lindenhayn K; Bühler G
Beitr Orthop Traumatol; 1989 Mar; 36(3):81-91. PubMed ID: 2499303
[TBL] [Abstract][Full Text] [Related]
39. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis.
Lange U; Teichmann J; Strunk J; Müller-Ladner U; Schmidt KL
Osteoporos Int; 2005 Dec; 16(12):1999-2004. PubMed ID: 16172800
[TBL] [Abstract][Full Text] [Related]
40. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
Plotkin H; Gundberg C; Mitnick M; Stewart AF
J Clin Endocrinol Metab; 1998 Aug; 83(8):2786-91. PubMed ID: 9709948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
